Connor Clark & Lunn Investment Management Ltd. Takes Position in Encompass Health Co. (NYSE:EHC)

Connor Clark & Lunn Investment Management Ltd. acquired a new position in Encompass Health Co. (NYSE:EHC) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 18,397 shares of the company’s stock, valued at approximately $1,778,000.

Several other large investors also recently made changes to their positions in EHC. Magnetar Financial LLC raised its stake in shares of Encompass Health by 1,176.6% during the second quarter. Magnetar Financial LLC now owns 744,836 shares of the company’s stock valued at $63,899,000 after purchasing an additional 814,018 shares in the last quarter. Thrivent Financial for Lutherans boosted its stake in Encompass Health by 2,302.7% during the 2nd quarter. Thrivent Financial for Lutherans now owns 603,558 shares of the company’s stock valued at $51,780,000 after purchasing an additional 578,438 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Encompass Health by 614.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 540,519 shares of the company’s stock valued at $44,637,000 after purchasing an additional 464,897 shares during the period. AQR Capital Management LLC raised its stake in shares of Encompass Health by 213.3% in the 2nd quarter. AQR Capital Management LLC now owns 207,202 shares of the company’s stock worth $17,776,000 after buying an additional 141,075 shares in the last quarter. Finally, Cubist Systematic Strategies LLC lifted its holdings in shares of Encompass Health by 762.4% in the second quarter. Cubist Systematic Strategies LLC now owns 83,347 shares of the company’s stock valued at $7,150,000 after buying an additional 73,683 shares during the period. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Stock Up 0.9 %

Shares of Encompass Health stock opened at $102.00 on Tuesday. The firm has a market cap of $10.28 billion, a price-to-earnings ratio of 24.64, a P/E/G ratio of 1.34 and a beta of 0.88. The stock has a 50-day simple moving average of $97.28 and a 200-day simple moving average of $90.99. Encompass Health Co. has a 52-week low of $63.78 and a 52-week high of $104.55. The company has a debt-to-equity ratio of 0.88, a current ratio of 1.04 and a quick ratio of 1.04.

Encompass Health (NYSE:EHC) last posted its earnings results on Monday, October 28th. The company reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.09. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.33 billion. Encompass Health had a net margin of 8.10% and a return on equity of 17.60%. The company’s revenue was up 11.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.86 earnings per share. On average, equities research analysts expect that Encompass Health Co. will post 4.29 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Thursday, January 2nd will be given a $0.17 dividend. The ex-dividend date of this dividend is Thursday, January 2nd. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.67%. Encompass Health’s dividend payout ratio is currently 16.43%.

Wall Street Analyst Weigh In

Several analysts recently commented on EHC shares. Royal Bank of Canada increased their target price on shares of Encompass Health from $105.00 to $110.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Barclays boosted their price objective on Encompass Health from $109.00 to $116.00 and gave the stock an “overweight” rating in a report on Tuesday, October 29th. UBS Group raised their target price on shares of Encompass Health from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. Stephens restated an “overweight” rating and set a $105.00 price target on shares of Encompass Health in a report on Tuesday, August 6th. Finally, KeyCorp boosted their target price on shares of Encompass Health from $115.00 to $117.00 and gave the company an “overweight” rating in a research note on Tuesday, October 29th. Nine investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $107.11.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.